VectorBuilder to Establish $50 Million Advanced Bio-Manufacturing and R&D Center in Chicago
VectorBuilder has announced a $50 million investment to build an integrated R&D and manufacturing center in Chicago, aimed at strengthening its North American supply chain and production capacity.
📋 Article Processing Timeline
- 📰 Published: May 28, 2026 at 15:50
- 🔍 Collected: May 28, 2026 at 07:05
- 🤖 AI Analyzed: May 28, 2026 at 07:05 (0 min after Collected)
CHICAGO (May 27, 2026) — VectorBuilder, a global leader in gene delivery technologies, today announced its plan to invest approximately $50 million to establish a new advanced bio-manufacturing and research and development (R&D) center in Chicago, Illinois. This facility is designed to expand the company’s regional footprint and reinforce the long-term infrastructure supporting genomic medicine.
The new center will serve as an integrated hub combining R&D and manufacturing capabilities for VectorBuilder’s gene delivery platform. Development will occur in phases, with operations expected to commence in 2027. Following the launch, the facility is planned to scale progressively based on customer demand and project complexity.
In recent years, the Cell and Gene Therapy (CGT) sector has placed increasing emphasis on early-stage vector design that accounts for manufacturability, regulatory compliance, and clinical performance. As more programs advance toward clinical trials, there is a growing demand for platforms that offer seamless transition from research-grade production to large-scale manufacturing. This investment is a strategic response to these market dynamics.
"While the cell and gene therapy field experiences short-term fluctuations, we remain confident in its robust long-term growth," stated Dr. Bruce Lahn, Chief Scientist at VectorBuilder. "This investment reflects our conviction that gene delivery will play a pivotal role in the industry’s next growth phase. By leveraging the exceptional talent pool in the region, we will integrate R&D and manufacturing to meet the expanding global demand."
The Chicago facility will support a wide array of gene delivery technologies, including plasmids, recombinant viral vectors, non-viral vectors, and genetically modified cells. By integrating these functions into a unified workflow, VectorBuilder aims to facilitate the smooth transition from research-grade vectors to GMP manufacturing, enhancing overall development efficiency.
Dr. Christopher Mueth, Chief Operating Officer at VectorBuilder, added: "Chicago is rapidly emerging as a premier life sciences innovation hub. Its access to world-class research talent and its central geographic location within the U.S. allow us to provide superior support to clients seeking stronger synergy between R&D and manufacturing as their programs move into clinical stages."
The establishment of this center is expected to increase production capacity and significantly reduce lead times for North American clients. This is particularly critical for projects progressing from basic research to Investigational New Drug (IND) applications and clinical manufacturing, where speed and flexibility are paramount.
Dr. Luisa Iruela-Arispe, Chair of the Department of Cell and Developmental Biology at Northwestern University Feinberg School of Medicine, noted: "As the cell and gene therapy pipeline matures, access to sophisticated development and manufacturing infrastructure becomes increasingly vital. Strengthening these capabilities in North America will play a key role in accelerating the translation of research discoveries into clinical applications."
This new center will complement VectorBuilder’s existing global network across the United States, Europe, and Asia, further empowering the company to support the full spectrum of client needs from discovery to commercialization.
The new center will serve as an integrated hub combining R&D and manufacturing capabilities for VectorBuilder’s gene delivery platform. Development will occur in phases, with operations expected to commence in 2027. Following the launch, the facility is planned to scale progressively based on customer demand and project complexity.
In recent years, the Cell and Gene Therapy (CGT) sector has placed increasing emphasis on early-stage vector design that accounts for manufacturability, regulatory compliance, and clinical performance. As more programs advance toward clinical trials, there is a growing demand for platforms that offer seamless transition from research-grade production to large-scale manufacturing. This investment is a strategic response to these market dynamics.
"While the cell and gene therapy field experiences short-term fluctuations, we remain confident in its robust long-term growth," stated Dr. Bruce Lahn, Chief Scientist at VectorBuilder. "This investment reflects our conviction that gene delivery will play a pivotal role in the industry’s next growth phase. By leveraging the exceptional talent pool in the region, we will integrate R&D and manufacturing to meet the expanding global demand."
The Chicago facility will support a wide array of gene delivery technologies, including plasmids, recombinant viral vectors, non-viral vectors, and genetically modified cells. By integrating these functions into a unified workflow, VectorBuilder aims to facilitate the smooth transition from research-grade vectors to GMP manufacturing, enhancing overall development efficiency.
Dr. Christopher Mueth, Chief Operating Officer at VectorBuilder, added: "Chicago is rapidly emerging as a premier life sciences innovation hub. Its access to world-class research talent and its central geographic location within the U.S. allow us to provide superior support to clients seeking stronger synergy between R&D and manufacturing as their programs move into clinical stages."
The establishment of this center is expected to increase production capacity and significantly reduce lead times for North American clients. This is particularly critical for projects progressing from basic research to Investigational New Drug (IND) applications and clinical manufacturing, where speed and flexibility are paramount.
Dr. Luisa Iruela-Arispe, Chair of the Department of Cell and Developmental Biology at Northwestern University Feinberg School of Medicine, noted: "As the cell and gene therapy pipeline matures, access to sophisticated development and manufacturing infrastructure becomes increasingly vital. Strengthening these capabilities in North America will play a key role in accelerating the translation of research discoveries into clinical applications."
This new center will complement VectorBuilder’s existing global network across the United States, Europe, and Asia, further empowering the company to support the full spectrum of client needs from discovery to commercialization.
FAQ
What is the primary purpose of the new Chicago facility?
The facility is an integrated hub for research, development, and manufacturing of gene delivery technologies, designed to shorten lead times and increase capacity for North American clients.
When is the facility expected to become operational?
Operations are scheduled to begin in 2027, with phased expansions planned thereafter.
What types of products will be manufactured at this site?
The center will produce plasmids, recombinant viral vectors, non-viral vectors, and genetically modified cells.
Why was Chicago chosen as the location?
Chicago was selected for its rapid growth as a life sciences hub, its central U.S. location, and its access to a highly skilled research workforce.